Abstract
Left ventricular (LV) scar is a risk factor for sudden cardiac death and heart failure in hypertrophic cardiomyopathy (HCM). LV scar is frequent in HCM and evolves over time. Hence there is a need for LV scar detection and longitudinal monitoring. The current gold standard for LV scar detection is late gadolinium enhancement (LGE) on magnetic resonance imaging (MRI), which is limited by high cost and susceptibility to artifacts from implanted defibrillators. We introduce XplainScar, the first explainable machine learning method for LV scar detection and localization in HCM, using 12-lead electrocardiogram (ECG) data, which is not influenced by implanted devices. We use 500 patients from the JH-HCM Registry for model development, and 248 patients from the UCSF-HCM-Registry for validation. XplainScar combines unsupervised and self-supervised ECG representation learning, resulting in high precision (90%), sensitivity (95%), specificity (80%) and F1-score (90%) for scar detection in the basal, mid, and apical LV myocardium, with a processing time of <1 minute per 10 patients. Basal LV scar prediction by XplainScar is dominated by QRS features, and mid/apical LV scar by T wave features. XplainScar generalizes well to the held-out test UCSF data, with 88% precision, 90% sensitivity, 78% specificity, and F1-score of 89%. In summary, XplainScar demonstrates good performance for LV scar detection, and provides ECG signatures of basal, mid, and apical LV scar in HCM.
XplainScar is publicly available at https://github.com/KasraNezamabadi/XplainScar
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded in part by the NSF IIS EAGER grant #1650851, an award from the John Taylor Babbitt (JTB) foundation, startup funds from the UCSF Division of Cardiology (to MRA), and funds from the Department of Computer and Information Sciences at the University of Delaware.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The HCM Registries are approved by the Institutional Review Boards (IRB) of the Johns Hopkins (JH) and the University of California San Francisco (UCSF) Hospitals. Informed consent was obtained for use of medical records for research. Protected patient information was excluded from datasets used for machine learning methods.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
XplainScar is publicly available at https://github.com/KasraNezamabadi/XplainScar
